astex therapeutics limited

5

astex therapeutics limited Company Information

Share ASTEX THERAPEUTICS LIMITED
Live 
MatureMegaRapid

Company Number

03751674

Registered Address

436 cambridge science park, milton road, cambridge, CB4 0QA

Industry

Research and experimental development on biotechnology

 

Telephone

01223226200

Next Accounts Due

September 2025

Group Structure

View All

Directors

Harren Jhoti25 Years

Robert McQuade10 Years

View All

Shareholders

otsuka america inc 100%

astex therapeutics limited Estimated Valuation

£573.5m

Pomanda estimates the enterprise value of ASTEX THERAPEUTICS LIMITED at £573.5m based on a Turnover of £202.5m and 2.83x industry multiple (adjusted for size and gross margin).

astex therapeutics limited Estimated Valuation

£1.7b

Pomanda estimates the enterprise value of ASTEX THERAPEUTICS LIMITED at £1.7b based on an EBITDA of £145.9m and a 11.97x industry multiple (adjusted for size and gross margin).

astex therapeutics limited Estimated Valuation

£292.6m

Pomanda estimates the enterprise value of ASTEX THERAPEUTICS LIMITED at £292.6m based on Net Assets of £136m and 2.15x industry multiple (adjusted for liquidity).

Edit your figures and get a professional valuation report.

Astex Therapeutics Limited Overview

Astex Therapeutics Limited is a live company located in cambridge, CB4 0QA with a Companies House number of 03751674. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in April 1999, it's largest shareholder is otsuka america inc with a 100% stake. Astex Therapeutics Limited is a mature, mega sized company, Pomanda has estimated its turnover at £202.5m with rapid growth in recent years.

View Sample
View Sample
View Sample

Upgrade for unlimited company reports & a free credit check

Astex Therapeutics Limited Health Check

Pomanda's financial health check has awarded Astex Therapeutics Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 9 measures and has 2 areas for improvement. Company Health Check FAQs

Health Check Image
Health Rating5out of 5
positive_score

9 Strong

positive_score

0 Regular

positive_score

2 Weak

size

Size

annual sales of £202.5m, make it larger than the average company (£3.7m)

£202.5m - Astex Therapeutics Limited

£3.7m - Industry AVG

growth

Growth

3 year (CAGR) sales growth of 37%, show it is growing at a faster rate (11.4%)

37% - Astex Therapeutics Limited

11.4% - Industry AVG

production

Production

with a gross margin of 71.7%, this company has a lower cost of product (54.2%)

71.7% - Astex Therapeutics Limited

54.2% - Industry AVG

profitability

Profitability

an operating margin of 68.5% make it more profitable than the average company (-0.8%)

68.5% - Astex Therapeutics Limited

-0.8% - Industry AVG

employees

Employees

with 166 employees, this is above the industry average (49)

166 - Astex Therapeutics Limited

49 - Industry AVG

paystructure

Pay Structure

on an average salary of £136.2k, the company has a higher pay structure (£81.5k)

£136.2k - Astex Therapeutics Limited

£81.5k - Industry AVG

efficiency

Efficiency

resulting in sales per employee of £1.2m, this is more efficient (£130.1k)

£1.2m - Astex Therapeutics Limited

£130.1k - Industry AVG

debtordays

Debtor Days

it gets paid by customers after 12 days, this is earlier than average (52 days)

12 days - Astex Therapeutics Limited

52 days - Industry AVG

creditordays

Creditor Days

its suppliers are paid after 2 days, this is quicker than average (70 days)

2 days - Astex Therapeutics Limited

70 days - Industry AVG

stockdays

Stock Days

There is insufficient data available for this Key Performance Indicator!

- - Astex Therapeutics Limited

- - Industry AVG

cashbalance

Cash Balance

has cash to cover current liabilities for 190 weeks, this is more cash available to meet short term requirements (37 weeks)

190 weeks - Astex Therapeutics Limited

37 weeks - Industry AVG

debtlevel

Debt Level

it has a ratio of liabilities to total assets of 28.1%, this is a lower level of debt than the average (50%)

28.1% - Astex Therapeutics Limited

50% - Industry AVG

ASTEX THERAPEUTICS LIMITED financials

EXPORTms excel logo

Astex Therapeutics Limited's latest turnover from December 2023 is £202.5 million and the company has net assets of £136 million. According to their latest financial statements, Astex Therapeutics Limited has 166 employees and maintains cash reserves of £75.8 million as reported in the balance sheet.

Data source: Companies HousePomanda Estimates

Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009
Turnover202,455,603117,178,47992,355,17179,022,45176,516,39772,199,76655,493,23254,148,44738,192,23733,347,9035,579,6988,238,48213,770,6349,030,7429,992,398
Other Income Or Grants000000000000000
Cost Of Sales57,368,18743,334,51445,014,50037,800,58137,370,66534,061,71427,225,49028,198,49419,722,84916,850,3202,947,6364,266,4456,746,2874,211,3000
Gross Profit145,087,41673,843,96547,340,67141,221,87039,145,73238,138,05228,267,74225,949,95318,469,38816,497,5832,632,0623,972,0377,024,3474,819,4420
Admin Expenses6,381,9294,780,5661,821,7706,508,0035,576,1866,789,70819,310,7104,581,0719,646,8279,223,09426,208,09021,035,54713,567,03212,111,1453,801,516
Operating Profit138,705,48769,063,39945,518,90134,713,86733,569,54631,348,3448,957,03221,368,8828,822,5617,274,489-23,576,028-17,063,510-6,542,685-7,291,703-3,801,516
Interest Payable3,064,9071,547,518565,4631,419,4771,102,178087,507000000121,627574,320
Interest Receivable925,5355,786,929747,70075,291132,827195,96529,13098,10255,50639,37013,20925,056114,636190,98442,771
Pre-Tax Profit136,566,11573,302,81045,701,13833,369,68132,600,19531,544,3098,818,76521,082,7908,878,0677,313,859-23,562,819-17,038,454-6,428,049-7,222,346-4,333,065
Tax-14,565,802-7,576,453-5,833,480-3,507,011-3,601,065-3,538,171790,0413,993,599-12,040-8,350-26,4543,058,1672,006,1832,491,1941,316,900
Profit After Tax122,000,31365,726,35739,867,65829,862,67028,999,13028,006,1389,608,80625,076,3898,866,0277,305,509-23,589,273-13,980,287-4,421,866-4,731,152-3,016,165
Dividends Paid75,000,00050,000,00025,000,00025,000,00023,748,96312,000,00028,000,00000000000
Retained Profit47,000,31315,726,35714,867,6584,862,6705,250,16716,006,138-18,391,19425,076,3898,866,0277,305,509-23,589,273-13,980,287-4,421,866-4,731,152-3,016,165
Employee Costs22,614,34319,879,07618,051,19116,665,16014,971,14414,175,37612,808,64111,722,63410,678,4589,261,27410,608,6308,231,3598,056,5476,117,7476,061,018
Number Of Employees16615715614214013211710295817088857472
EBITDA*145,894,13675,531,90351,444,08939,561,00538,016,56633,553,65610,476,13522,568,6679,938,7718,104,498-22,893,782-16,431,586-6,080,668-6,773,548-3,104,022

* Earnings Before Interest, Tax, Depreciation and Amortisation

Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009
Tangible Assets50,209,30148,707,25646,450,07649,762,37443,660,88719,848,38618,012,2799,911,3934,673,8013,746,2332,583,6852,616,8692,512,0992,267,0552,347,160
Intangible Assets242,084346,105389,306249,862187,448208,478129,87225,88933,85146,1207,67314,5107,63413,96310,944
Investments & Other8,648,6287,991,1854,921,7596,138,3445,545,6434,315,7732,198,513962,8500000000
Debtors (Due After 1 year)002,049,02401,106,5620000000000
Total Fixed Assets50,451,38549,053,36146,839,38250,012,23643,848,33520,056,86418,142,1519,937,2824,707,6523,792,3532,591,3582,631,3792,519,7332,281,0182,358,104
Stock & work in progress000000000000045,55847,282
Trade Debtors6,944,3591,079,210607,614823,8298,411,62712,598,6774,940,3796,540,6822,820,3996,139,6102,243,63803,138,7421,936,500100,000
Group Debtors5,754,9644,773,7134,613,2525,373,83600000000000
Misc Debtors44,715,66424,857,94017,777,46812,448,8952,100,3603,005,2674,645,2876,024,7721,963,9722,171,4341,187,4191,412,6191,119,0811,112,2671,131,540
Cash75,794,37238,101,16232,385,43817,706,97023,936,01016,609,7078,063,27833,247,65221,013,24810,184,1594,006,2061,491,1008,120,86410,080,65713,356,342
misc current assets5,028,4533,082,7623,207,4192,484,26001,882,8152,913,0560003,002,0313,028,4851,917,3948,974,06516,274,005
total current assets138,795,91572,309,02458,591,19138,837,79037,700,50434,096,46620,562,00045,813,10625,797,61918,495,20310,439,2945,932,20414,296,08122,149,04730,909,169
total assets189,247,300121,362,385105,430,57388,850,02681,548,83954,153,33038,704,15155,750,38830,505,27122,287,55613,030,6528,563,58316,815,81424,430,06533,267,273
Bank overdraft000000000000000
Bank loan000000000000000
Trade Creditors 449,652360,509620,0421,205,985893,0541,199,215847,854641,5911,161,1041,497,398323,5601,988,4251,963,7781,260,355741,524
Group/Directors Accounts000000000000199,35700
other short term finances000000000000002,774,317
hp & lease commitments2,953,1362,345,3212,068,0112,085,1552,101,3620000000000
other current liabilities17,236,7995,585,9296,877,7705,069,2864,921,0283,377,8364,286,1573,147,4632,459,2222,771,24043,244,72013,093,8155,621,0766,009,0254,817,790
total current liabilities20,639,5878,291,7599,565,8238,360,4267,915,4444,577,0515,134,0113,789,0543,620,3264,268,63843,568,28015,082,2407,784,2117,269,3808,333,631
loans36,334,76634,633,90033,531,72036,784,36239,836,2860000000000
hp & lease commitments18,167,38317,316,95016,765,86018,392,18119,918,1430000000000
Accruals and Deferred Income8,317,22200483,650000000001,805,5615,694,4489,861,112
other liabilities540,5471,185,824882,280640,474139,8440000000000
provisions11,100,31011,071,5189,821,7485,070,43400000000000
total long term liabilities32,575,30724,038,53322,559,01422,051,52220,057,98700000001,805,5615,694,4489,861,112
total liabilities53,214,89432,330,29232,124,83730,411,94827,973,4314,577,0515,134,0113,789,0543,620,3264,268,63843,568,28015,082,2409,589,77212,963,82818,194,743
net assets136,032,40689,032,09373,305,73658,438,07853,575,40849,576,27933,570,14051,961,33426,884,94518,018,918-30,537,628-6,518,6577,226,04211,466,23715,072,530
total shareholders funds136,032,40689,032,09373,305,73658,438,07853,575,40849,576,27933,570,14051,961,33426,884,94518,018,918-30,537,628-6,518,6577,226,04211,466,23715,072,530
Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009
Operating Activities
Operating Profit138,705,48769,063,39945,518,90134,713,86733,569,54631,348,3448,957,03221,368,8828,822,5617,274,489-23,576,028-17,063,510-6,542,685-7,291,703-3,801,516
Depreciation6,990,2126,304,2275,811,7984,765,0224,350,7192,142,4161,475,3711,175,9551,094,460810,638675,409624,849455,688511,276690,735
Amortisation198,437164,277113,39082,11696,30162,89643,73223,83021,75019,3716,8377,0756,3296,8796,759
Tax-14,565,802-7,576,453-5,833,480-3,507,011-3,601,065-3,538,171790,0413,993,599-12,040-8,350-26,4543,058,1672,006,1832,491,1941,316,900
Stock000000000000-45,558-1,72447,282
Debtors26,704,1245,663,5056,400,7987,028,011-3,985,3956,018,278-2,979,7887,781,083-3,526,6734,879,9872,018,438-2,845,2041,209,0561,817,2271,231,540
Creditors89,143-259,533-585,943312,931-306,161351,361206,263-519,513-336,2941,173,838-1,664,86524,647703,423518,831741,524
Accruals and Deferred Income19,968,092-1,291,8411,324,834631,9081,543,192-908,3211,138,694688,241-312,018-40,473,48030,150,9055,667,178-4,276,836-2,975,42914,678,902
Deferred Taxes & Provisions28,7921,249,7704,751,3145,070,43400000000000
Cash flow from operations124,710,23761,990,34144,700,01635,041,25639,637,92723,440,24715,590,92118,949,91112,805,092-36,083,4813,547,366-4,836,390-8,811,396-8,554,45512,354,482
Investing Activities
capital expenditure-8,586,673-8,682,483-2,752,334-11,011,039-28,238,491-4,120,025-9,723,972-6,429,415-2,031,509-2,031,004-642,225-743,570-700,732-441,069-3,055,598
Change in Investments657,4433,069,426-1,216,585592,7011,229,8702,117,2601,235,663962,8500000000
cash flow from investments-9,244,116-11,751,909-1,535,749-11,603,740-29,468,361-6,237,285-10,959,635-7,392,265-2,031,509-2,031,004-642,225-743,570-700,732-441,069-3,055,598
Financing Activities
Bank loans000000000000000
Group/Directors Accounts00000000000-199,357199,35700
Other Short Term Loans 0000000000000-2,774,3172,774,317
Long term loans1,700,8661,102,180-3,252,642-3,051,92439,836,2860000000000
Hire Purchase and Lease Commitments1,458,248828,400-1,643,465-1,542,16922,019,5050000000000
other long term liabilities-645,277303,544241,806500,630139,8440000000000
share issue0000-1,251,038100041,251,037-429,698235,588181,6711,124,85918,088,695
interest-2,139,3724,239,411182,237-1,344,186-969,351195,965-58,37798,10255,50639,37013,20925,056114,63669,357-531,549
cash flow from financing374,4656,473,535-4,472,064-5,437,64959,775,246195,966-58,37798,10255,50641,290,407-416,48961,287495,664-1,580,10120,331,463
cash and cash equivalents
cash37,693,2105,715,72414,678,468-6,229,0407,326,3038,546,429-25,184,37412,234,40410,829,0896,177,9532,515,106-6,629,764-1,959,793-3,275,68513,356,342
overdraft000000000000000
change in cash37,693,2105,715,72414,678,468-6,229,0407,326,3038,546,429-25,184,37412,234,40410,829,0896,177,9532,515,106-6,629,764-1,959,793-3,275,68513,356,342

astex therapeutics limited Credit Report and Business Information

Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for astex therapeutics limited. Get real-time insights into astex therapeutics limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Astex Therapeutics Limited Competitor Analysis

BETA
competitor_analysis_table_img

Perform a competitor analysis for astex therapeutics limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.

astex therapeutics limited Ownership

ASTEX THERAPEUTICS LIMITED group structure

Astex Therapeutics Limited has no subsidiary companies.

Ultimate parent company

OTSUKA HOLDINGS CO LTD

#0071689

OTSUKA AMERICA INC

#0043666

2 parents

ASTEX THERAPEUTICS LIMITED

03751674

ASTEX THERAPEUTICS LIMITED Shareholders

otsuka america inc 100%

astex therapeutics limited directors

Astex Therapeutics Limited currently has 5 directors. The longest serving directors include Harren Jhoti (May 1999) and Dr Robert McQuade (Jan 2014).

officercountryagestartendrole
Harren Jhoti61 years May 1999- Director
Dr Robert McQuade67 years Jan 2014- Director
Professor Sir Thomas BlundellEngland81 years Jan 2014- Director
Mr Toshiki Sudo55 years May 2015- Director
Dr Yasuhisa Kurogi59 years Mar 2024- Director

P&L

December 2023

turnover

202.5m

+73%

operating profit

138.7m

+101%

gross margin

71.7%

+13.72%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

December 2023

net assets

136m

+0.53%

total assets

189.2m

+0.56%

cash

75.8m

+0.99%

net assets

Total assets minus all liabilities

astex therapeutics limited company details

company number

03751674

Type

Private limited with Share Capital

industry

72110 - Research and experimental development on biotechnology

incorporation date

April 1999

age

25

accounts

Full Accounts

ultimate parent company

OTSUKA HOLDINGS CO LTD

previous names

astex technology limited (June 2005)

intercede 1426 limited (May 1999)

incorporated

UK

address

436 cambridge science park, milton road, cambridge, CB4 0QA

last accounts submitted

December 2023

astex therapeutics limited Charges & Mortgages

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We found 2 charges/mortgages relating to astex therapeutics limited. Currently there are 0 open charges and 2 have been satisfied in the past.

charges

astex therapeutics limited Companies House Filings - See Documents

datedescriptionview/download